(SeaPRwire) – By: Ethan Gallagher
The hype around Neuralink’s flashy demos has blinded many to a critical reality. China’s Neuracle just took the lead in commercial brain-computer interfaces—not with grand promises of replacing phones, but with a practical, non-invasive device that solves a real problem for patients.
Official releases confirm Neuracle’s NEO chip is a coin-sized implant placed on the brain’s surface. It was approved by China’s medical regulator in March. A Shanghai hospital performed the world’s first commercial procedure on a patient with a 10-year spinal cord injury from a car accident. The operation went as planned; the device captured stable, high-quality brain signals. The patient’s vital signs are stable. The subtext here is unmissable: non-invasive implants avoid the risks of penetrating brain tissue. That means faster regulatory approval. Neuralink’s thread-based approach, which inserts ultra-thin threads into brain tissue, can’t match this speed. It requires more rigorous testing to prove it won’t cause long-term damage.
Official facts state Neuralink has 21 trial patients worldwide but no full U.S. commercial approval. The subtext? Invasive devices face higher regulatory hurdles. Other players are also in the game: Synchron uses a vein-inserted implant, and Meta works on AI that translates non-invasive brain scans into text. But Neuracle is the first to move beyond trials and into hospitals. This isn’t just a win for Neuracle—it’s a shift in the BCI landscape. Medical providers will prioritize non-invasive tools first because they’re safer and easier to adopt.
The BCI supply chain will now split along these lines. Manufacturers that can produce surface-mounted chips and compatible robotic gloves will dominate the medical segment. Invasive tech like Neuralink’s will lag until it passes stricter safety checks. This split will define the next five years of BCI development—medical use cases first, consumer applications later.
Author bio: Ethan Gallagher, Silicon Valley Hardware Architect and Infrastructure Strategist with expertise in medical device design and regulatory pathways.